Making Malaria-Treatment Policy in the Face of Drug Resistance

Ann Trop Med Parasitol. 1999 Jan;93(1):5-23. doi: 10.1080/00034989958753.

Abstract

The threat, development, spread, and intensification of antimalarial drug resistance are posing tremendous challenges to malaria-control activities throughout the world. Fundamental aspects of these activities are the identification and promotion of safe and effective therapy for acute malarial illness. A major tool in providing guidance on appropriate therapy is the national malaria-therapy policy, which describes antimalarial drugs available for use in a given country, their relative efficacy, and how best to use them in a variety of settings, from the community to the referral hospital. This review describes some of the factors that need to be considered in the development of a national, antimalarial drug policy as well as those that have impeded timely development of national policies, especially in sub-Saharan Africa.

Publication types

  • Review

MeSH terms

  • Africa South of the Sahara
  • Antimalarials / therapeutic use
  • Asia, Southeastern
  • Chloroquine / therapeutic use
  • Community Health Services
  • Disease Outbreaks
  • Drug Resistance*
  • Health Policy
  • Humans
  • Malaria / drug therapy*
  • Malaria / prevention & control
  • Patient Acceptance of Health Care

Substances

  • Antimalarials
  • Chloroquine